Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Breaks Above Two Hundred Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $5.62 and traded as high as $8.34. Cumberland Pharmaceuticals shares last traded at $7.94, with a volume of 76,217 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Trading Down 5.0%

The stock has a market capitalization of $114.00 million, a price-to-earnings ratio of -10.72 and a beta of 0.13. The stock’s 50 day moving average is $7.34 and its two-hundred day moving average is $5.65.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%.

Cumberland Pharmaceuticals Announces Dividend

The company also recently disclosed a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were issued a dividend of $1.50 per share.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of large investors have recently bought and sold shares of CPIX. Dimensional Fund Advisors LP grew its stake in shares of Cumberland Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock worth $898,000 after acquiring an additional 4,081 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Cumberland Pharmaceuticals in the second quarter worth $412,000. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals in the second quarter worth $379,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Cumberland Pharmaceuticals during the first quarter worth $66,000. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company’s business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States.

Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation.